Varegacestat
Small molecule
Evidence outlook · regulatory review
Desmoid Tumors: application under FDA review, decision date 2027-04-28
FDA accepts the NDA for varegacestat in desmoid tumors (2026-07-08). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
RINGSIDE (NCT04871282): This was a randomized, quadruple-masked Phase 2/3 trial with 198 participants. Its primary endpoint was met according to the sponsor's announcement of 2025-12-15. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Company guidance: regulatory filing expected by the end of 2026 (Immunome, Inc., 11 Aug 2026). “Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RINGSIDE NCT04871282 · Desmoid Tumors This was a randomized, quadruple-masked Phase 2/3 trial with 198 participants. Its primary endpoint was met according to the sponsor's announcement of 2025-12-15. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate. Registry: NCT04871282 | 2/3 | Part A: Safety and Tolerability - Adverse Events (Approximately 1.5 years); Part B: Progression free survival (PFS) (Approximately 2 years) 2025-12-03 | Primary endpoint, progression-free survival vs placebo: HR 0.16 (95% CI 0.071-0.375; p<0.0001); confirmed ORR 56% vs 9% (RINGSIDE, 2025-12-15). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Gamma-secretase (presenilin complex) drugs
Nirogacestat. Compare all 2 Gamma-secretase (presenilin complex) drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Desmoid Tumors: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Varegacestat: this drug | Phase 2/3 | Small molecule | Gamma-secretase (presenilin complex) | Partial signal | NCT04871282: Primary endpoint, progression-free survival vs placebo: HR 0.16 (95% CI 0.071-0.375; p<0.0001); confirmed ORR 56% vs 9% (RINGSIDE, 2025-12-15). | |
| Nirogacestat | Approved | Small molecule | Gamma-secretase (presenilin complex) | Reliable signal | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Varegacestat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
May 2027 (1)
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent